MedTrace Logo

Emla-Cream as Pain Relief During Pneumococcal Vaccination

NCT01802086 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-10-23

Study results available
· View outcomes & findings →

Summary

The aim of this intervention study is to compare the efficacy of Emla cream as a pain relief or no pain relief in connection to the first pneumococcal vaccination at the age of three months in Child health care.

Primary objective

1.Leads Emla cream as pain relief to children in connection with pneumococcal vaccination at the age of three months to lower pain scores in the use of five items; Face, Legs, Activity, Cry, Consolability (FLACC scale) as a pain measurement instrument?

Conditions

Interventions

DRUG

Emla-cream

Topical anaesthetic

DRUG

Miniderm cream

Topical

Sponsors & Collaborators

  • Beatrice Olsson Duse

    lead OTHER

Principal Investigators

  • Marco Bartocci, MD, PhD · Astrid Lindren Children´s Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
4 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802086 on ClinicalTrials.gov